Johnson & Johnson has agreed to pay as much as $2.2 billion to settle U.S. probes of the marketing of its Risperdal antipsychotic drug and other medications, two people familiar with the negotiations said.
J&J said to pay $2.2 billion to end Risperdal sales probe
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.